VITASPRING BIOMEDICAL CO. LTD.

VitaSpring Biomedical Co. Ltd.

Corporate status and focus

• Development-stage biomedical company incorporated in Nevada on September 6, 2016 (formerly Shemn Corp.).
• Began operations in 2019. Ownership change on January 21, 2020; corporate name changed to VitaSpring Biomedical Co. Ltd., effective April 21, 2020 after FINRA clearance.
• Fiscal year end: January 31.
• Core focus: research, development, and potential commercialization of cell-based biomedical technologies, with emphasis on regenerative medicine, preventive health, beauty, and anti-aging applications.

Programs and technology

• Principal technologies: X.msc mesenchymal stem cells derived from ethically sourced non-embryonic placental tissue, and exosome-based materials derived from those cells.
• Current activities: research and development, production-process improvement, and evaluation of potential future applications. The company does not sell products or treatments to consumers at this time.
• Planned production and regulatory preparation: aims to develop GTP/GMP-aligned production capabilities and a stem-cell bank to operate under applicable FDA regulations for future regulatory pathways.
• Internal testing claims: management reports higher exosome concentrations in X.msc-derived cultures relative to some conventional MSC cultures; those results have not been independently validated or reviewed by regulators.

Intellectual property and data

• As of the filing, no issued patents or registered trademarks are owned by the company.
• Proprietary assets: trade secrets, technical know-how, and internal research data.
• IP strategy: pursue patent and trademark protection as development progresses; use confidentiality agreements to protect information.
• Data and cybersecurity: plans to implement data protection and cybersecurity measures; a formal cybersecurity framework was not yet in place as of the filing.

Market opportunity and positioning

• Industry focus: global regenerative medicine and functional wellness sectors, including cell therapy, exosome research, skincare, and anti-inflammatory research.
• Market context cited: regenerative medicine market estimates referenced in the filing for 2025–2026 and projected ongoing growth as regulatory frameworks mature.
• Target markets:
  • Regenerative medicine (allogeneic MSCs and exosome materials for research, trials, and development)
  • Biomedical research and contract manufacturing services (cell production, purification, QC)
  • Preventive health and anti-aging (future consumer-oriented exosome formulations for skincare and tissue repair)
  • Collaborative R&D with universities, hospitals, and biotech firms

Business model and revenue strategy

• Development-stage with limited or no revenue to date.
• Near-term focus: create intellectual property, establish production know-how, and pursue partnerships.
• Potential future revenue sources: product or licensing revenue, contract research and manufacturing fees, and collaborative or joint-venture arrangements.
• B2B orientation: pricing and customer approach aimed at institutional and clinical clients rather than direct retail consumers.

Collaborations and partnerships

• Existing relationships primarily in Taiwan and other Asia‑Pacific regions; no formal North American partnerships at the filing date.
• Potential collaborations with universities, hospitals, CROs, contract manufacturers, and biotechnology firms to support development, regulatory readiness, testing, manufacturing, and distribution.

Regulatory stance and compliance

• As of the filing, no FDA submissions, no clinical programs, and no approval to market regulated products.
• Long-term compliance goals include establishing GTP/GMP-aligned production facilities in anticipation of regulatory submissions.

Operations, employees, and facilities

• Employees: as of January 31, 2025, no full-time employees other than a sole executive who holds all officer positions; operations are conducted by contractors, consultants, scientists, and research partners.
• Hiring plans: intended recruitment in R&D, quality assurance, regulatory affairs, and business development as financing becomes available.
• Facilities: virtual office lease at 5225 Canyon Crest Drive, Suite 71-825, Riverside, CA 92507 with rent of $25 per month; previously maintained a Taiwan branch and an Irvine, CA executive office; relocated to Riverside in May 2025.

Financial condition (high-level snapshot)

• Cash: $272 (as of the cited period in 2025)
• Total assets: $14,378
• Total liabilities: $4,029,578
• Accumulated deficit: $5,281,503
• Stockholders’ deficit: $4,015,200
• Negative operating cash flows: $14,675
• Revenue: no revenue in fiscal years ended January 31, 2025 and January 31, 2024
• Going concern: the company reported substantial doubt about its ability to continue as a going concern within twelve months from the financial statement date; operations depend on additional capital or continued financial support from related parties
• Related-party obligations (as of the filing period): $2,411,000 owed to a related-party vendor (owned by a former officer); $810,105 in advances from related parties (including advances by a former CEO and Chairman)
• Post-period development (May 18, 2026): entered a deferred payment agreement with the related party on the $2,411,000 accounts payable, deferring collection for 24 months; this agreement does not include related-party advances
• Governance and controls: identified a material weakness in internal control over financial reporting related to segregation of duties and limited U.S. GAAP/SEC reporting expertise

Governance and risk considerations

• Governance structure: a single director who is also the sole executive officer; no independent directors or formal related-party transaction policy noted in the filing.
• Legal matters: former officers and directors are involved in civil and criminal proceedings in Taiwan relating to alleged unauthorized use of intellectual property; the filing flags potential reputational and financial implications.
• Regulatory and market risk: the regulatory landscape for stem-cell and exosome technologies is evolving; the company faces regulatory and financing risks common to development-stage biotechnology firms.
• Cybersecurity: no formal policy in place at the filing date; plans to implement a formal program.

Company statements

• The company does not sell products or treatments to consumers at this time.
• Current activities are focused on R&D, process improvement, and evaluating future applications.
• Any future consumer or patient products would require scientific validation and regulatory approvals (FDA or equivalent) before being offered for sale.